Table 1 Patient and treatment characteristics.

From: Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients

	Total		C-PCI		HA-PCI		p value
	n = 106	%	n = 58	%	n = 48	%	p value
Age, years
Median	65		65		64		0.424
(Range)	(37–82)		(53–82)		(37–79)
Sex
Male	93	87.7	54	93.1	39	81.3	0.064
Female	13	12.3	4	6.9	9	18.8
ECOG PS
0, 1	101	95.3	55	94.8	45	93.8	0.842
2	5	4.7	3	5.2	2	4.2
T stage
T1	17	16.0	7	12.1	10	20.8	0.127
T2	33	31.1	21	36.2	12	25.0
T3	25	23.6	10	17.2	15	31.3
T4	31	29.2	20	34.5	11	22.9
N stage
N0	12	11.3	8	13.8	4	8.3	0.741
N1	13	12.3	8	13.8	5	10.4
N2	57	53.8	30	51.7	27	56.3
N3	24	22.6	12	20.7	12	25.0
AJCC stage (7th edition)
I	7	6.6	5	8.6	2	4.2	0.796
II	11	10.4	6	10.3	5	10.4
IIIA	43	40.6	22	37.9	21	43.8
IIIB	45	42.5	25	43.1	20	41.7
Initial treatment
RT alone	1	0.9	0	0.0	1	2.1	0.063
Concurrent CRT	98	92.5	51	87.9	47	97.9
Sequential CRT	4	3.8	4	6.9	0	0.0
Surgery	3	2.8	3	5.2	0	0.0
Chemotherapy regimen
None	1	0.9	0	0.0	1	2.1	0.114
EP	102	96.2	55	94.8	47	97.9
Others	3	2.8	3	5.2	0	0.0
Chemotherapy cycles
4	69	65.1	43	74.1	26	54.2	0.043
6	36	34.0	15	25.9	21	43.8
Thoracic RT dose (Gy)
Median	54		54		63		< 0.001
(Range)	(30.6–70.2)		(37.-64.5)		(30.6–72)
Thoracic RT fraction size (Gy)
Median	2		2		2.1		0.097
(Range)	(1.5–15)		(1.8–15)		(1.5–2.5)
Thoracic RT fractions
Median	30		28		30		0.036
(Range)	(3–35)		(3–33)		(17–35)
Thoracic RT total dose (EQD2)
< 60 Gy	38	84.4	5	11.1	43	47.8	< 0.001
≥ 60 Gy	7	15.6	40	88.9	47	52.2
Thoracic RT modality
3D CRT	52	50.5	49	89.1	3	6.3	< 0.001
IMRT	51	49.5	6	10.9	45	93.8
Initial treatment response
CR	9	8.5	8	13.8	1	2.1	0.023
PR	94	88.7	47	81.0	47	97.9
SD	3	2.8	3	5.2	0	0.0
PCI modality
3D CRT	57	53.8	56	96.6	0	0.0	< 0.001
IMRT	49	46.2	2	3.4	48	100.0
Interval, initial treatment to PCI (days)
Median	112		125		105		0.003
(Range)	(68–312)		(69–312)		(68–167)
Interval, last treatment to PCI (days)
Median	28		28		27		0.424
(Range)	(0–146)		(7–146)		(0–116)
Treatment period
Median	2014		2011		2017		< 0.001
(Range)	(2007–2018)		(2007–2016)		(2015–2018)

C-PCI conventional prophylactic cranial irradiation, HA-PCI hippocampus-avoidance PCI, ECOG PS Eastern Cooperative Oncology Group Performance Status, AJCC American Joint Committee on Cancer, RT radiotherapy, CRT chemoradiotherapy, EP etoposide/cisplatin, EQD2 Equivalent dose in 2 Gy fractions, α/β = 10, 3D-CRT 3-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, CR complete response, PR partial response, SD stable disease.

Back to article page

Table 1 Patient and treatment characteristics.

Search

Quick links